Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 27

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 27
---
 unpaid due to David Koos as of September 30, 2024..

*On March 17, 2023 David Koos was issued 15,000 Series NC Preferred shares in satisfaction of $10,050 of salaries accrued yet unpaid.

| 24 |

Employment Agreements

Currently neither the Company nor the Company’s wholly owned subsidiary is party to any employment agreement.

BUSINESS

We were incorporated April 24, 2012 under the laws of the State of Nevada. We intend to engage primarily in the development of regenerative medical applications which we intend to license, develop internally or acquire outright from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

As of February 27, 2025 we have not licensed any existing therapies which may be marketed.

Patents :

The following is a list of intellectual property (“IP”) controlled by either Regen Biopharma, Inc. (the “Company”) or KCL Therapeutics (“KCL”). KCL is a wholly owned subsidiary of the Company. IP which has been granted patent protection by the United States Patent and Trademark Office (“USPTO”)

| ● | GENE                                                                                                                                      
 SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS)                                                                      |
|   | Provides                                                                                                                                  
 methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory        
 of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which      
 results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy         
 can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.          |
|   | Patent                                                                                                                                    
 No: 8263571                                                                                                                               |
| ● | METHODS                                                                                                                                   
 AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION                                       |
|   | Means,                                                                                                                                    
 methods, and compositions of matter